Stockreport

Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma [Yahoo! Finance]

Novo Nordisk A/S  (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
PDF Under the terms, Novo Nordisk has acquired the Hemophilia A program and rights to 2seventy's in vivo gene editing technology outside of oncology and gene editing for au [Read more]